NON MUSCLE INVASIVE BLADDER CANCER

This phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…

This study tests whether a combination of two chemotherapy drugs (gemcitabine and docetaxel, or GEMDOCE) works as well as the standard BCG treatment for people with a high-grade, non-muscle invasive bladder cancer that hasn't been treated before. About 870 adults will be randomly…

This early-stage study tests a new treatment called TAR-210 in 5 Japanese patients with a type of bladder cancer that has specific genetic changes (FGFR mutations). The treatment is placed directly into the bladder to deliver the drug erdafitinib. The main goal is to see if it is…

This phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard BCG treatment can safely control high-risk non-muscle-invasive bladder cancer. About 100 adults who have never received BCG before will get both treatments for up to a year. The main goal i…

This study tests whether adding the immunotherapy drug durvalumab to standard BCG treatment helps keep high-risk bladder cancer from coming back. About 1,000 adults with non-muscle-invasive bladder cancer who have not had BCG before will receive either the combination or BCG alon…

This study tests whether adding an immune-boosting drug called N-803 to the standard BCG treatment works better than BCG alone for people with a high-risk type of bladder cancer that hasn't invaded the muscle. About 369 participants will receive either the combination or BCG alon…

This early-stage trial tests a treatment called CG0070, a virus-based therapy given directly into the bladder, after standard surgery for intermediate-risk non-muscle invasive bladder cancer. About 20 participants will receive the treatment to see if it is safe and helps prevent …

This phase 3 trial is testing a new treatment called cretostimogene grenadenorepvec for people with a type of bladder cancer (non-muscle invasive) that did not improve after standard BCG therapy. The treatment uses a modified virus to target and destroy cancer cells. About 190 pa…

This study looks at whether eating a diet rich in cruciferous vegetables (like broccoli, cauliflower, and cabbage) can help prevent bladder cancer from coming back in people with intermediate to very high-risk non-muscle invasive bladder cancer. About 250 participants will either…

This phase 3 trial tests whether adding the immunotherapy drug sasanlimab to standard BCG treatment helps control high-risk non-muscle invasive bladder cancer better than BCG alone. Over 1,000 participants are enrolled, with some receiving the combination and others BCG only. The…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study looks at whether a test that checks for a specific gene marker (SIX6) in urine or tissue can predict if bladder cancer will come back after surgery. Researchers will compare SIX6 levels in 177 patients who had low-risk bladder cancer to see if the test can tell who is …

This phase II trial tests whether a low-dose version of the drug rapamycin, called eRapa, can prevent bladder cancer from coming back in people who have already been treated for non-muscle invasive bladder cancer. About 166 participants will take eRapa or a placebo daily for one …

This Phase 3 trial tests whether a therapeutic BCG vaccine, given directly into the bladder, can prevent non-muscle-invasive bladder cancer from returning after surgery. About 439 adults with intermediate- or high-risk cancer are participating. The study compares BCG to an active…

This study looks at whether reducing the time BCG stays in the bladder (dwell-time) can lessen severe side effects in people with high-risk non-muscle invasive bladder cancer. About 314 patients from Nordic countries will either get the standard dwell-time or a shorter one based …

This study compares two common treatments for recurrent non-muscle-invasive bladder cancer: medical therapy (drugs placed in the bladder) and surgery (bladder removal). Researchers will track quality of life and patient experiences in 570 adults to see which approach works better…

This study follows 6 patients who previously received an experimental treatment (N-803 plus BCG) for non-muscle invasive bladder cancer. Researchers will collect long-term data on survival, cancer recurrence, and test results to see how well the treatment worked over time. No new…

This study follows 600 people with non-muscle invasive bladder cancer to see how changes in smoking habits and body weight after diagnosis affect the chance of cancer coming back. Participants fill out questionnaires and provide saliva or urine samples over time. The goal is to l…